Sandra Calvin, SVP, Chief Accounting Officer at Travere Therapeutics, Inc. (TVTX), sold 2,031 shares at $21.75 ($44K) on 2023-02-01, disclosed to the SEC on 2023-02-02.
Scheduled sale ($44k) by SVP, Chief Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.75 | 1,671 | $36K | 81.8% |
| 2 | $22.42 | 360 | $8K | 18.2% |
| Total | $21.87 avg | 2,031 | $44K | 100% |
| Filing → |
| TVTX | SELL | 2026-02-03 | $139K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |